Home > Online bookshop > Books
 
      Advanced search    Shopping cart    French version 
 
Latest books
Catalogue/Search
Collections

Google Book Search
All journals
Medicine
Biology and research
Public health
Agronomy and biotech.
My account
Forgotten password?
Online account   activation
Subscribe
Licences IP
- Instructions for use
- Estimate request form
- Licence agreement
Order an issue
Pay-per-view articles
Newsletters
How can I publish?
Journals
Books
Help for advertisers
Foreign rights
Book sales agents



 

Printable version
Les lymphomes non hodgkiniens

Non-Hodgkin's lymphoma

Christian Gisselbrecht

2009

Series : Collection FMC de la revue Hématologie

Find out the books of Collection FMC de la revue Hématologie

ISBN : 978-2-7420-0646-5

128 pages

Specialty : Oncology, Hematology

Published in : French


Sommaire (fr)

 Price : 25.00 €
Add to shopping cart   |  One-click order
Search the full text of this book:

Google Book Search
This is the second edition of the book devoted to Non-Hodgkin's lymphoma in the "Haematology series".
While all the chapters have been reworked, the book has been written in the same spirit as the earlier version: the aim is to inform oncologists-haematologists treating patients with the disease and to help train their less experienced colleagues.
Written by eminent specialists in the field who have been involved in the development of clinical trials through the GELA* for twenty years, this work provides a synthesis of recent breakthroughs and will serve as a practical guide for clinicians and pathobiologists alike.
Since the year 2000, when the first edition was published, impressive progress has been made in all fields, including epidemiology, clinical aspects and therapies.
All treatment strategies have been modified as a result of the large randomized studies conducted in Europe and this must be brought to the attention of clinicians working with the disease.
Treatments have also undergone major changes through the introduction of humanised anti-CD20 monoclonal antibodies in all B-cell lymphomas, which have led to an overall improvement in the survival rates.
Future progress will depend on the arrival of new treatments more closely targeting both already known and yet to be discovered carcinogenesis pathways, with the aim of developing antitumour vaccines for type B lymphomas.
*GELA: Groupe d’Étude des Lymphomes de l’Adulte (Adult lymphoma study group)
 

About us - Contact us - Conditions of use - Secure payment
Latest news - Conferences
Copyright © 2007 John Libbey Eurotext - All rights reserved
[ Legal information - Powered by Dolomède ]